Propafenone

Cardiac Electrophysiology Review

Volumn 2, Issue 2, 1998, Pages 204-206

  Joglar, Jose A ^a   Hamdan, Mohamed H ^a   Page, Richard L ^a,b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2342451422     PISSN: 13852264     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009988218428     Document Type: Article

References (13)

1. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J 1984;5:115-125.
2. Thompson KA, Iansmith DHS, Siddoway LA, Woosley RL, Roden DM. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther 1988;244:950-955.
3. Gonzalez FJ, Meyer UA. Molecular genetics of the drebrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991; 50:233-238.
4. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism clinical aspects. Pharmac Ther 1990;46:377-394.
5. Stoobrand R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997;79:418-423.
6. Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeois M. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J 1994;15:1050-1056.
7. Salerno DM, Gillingham KJ, Berry DA, Hodges M. A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: a meta-analysis. Am Heart J 1990;120:340-353.
8. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
9. Hernandez M, Reder RF, Merinchak RA, Rials SJ, Kowey PR. Propafenone for malignant ventricular arrhythmias: An analysis of the literature. Am Heart J 1991;121:1178-1184.
10. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-458.
11. Siebels J, Cappato R, Ruppel R, et al. Implantable cardioverter defibrillator compared with antiarrhythmic drug in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J 1994;127:1139-1144.
12. Stevens SK, Haffajee CI, Naccarelli GV, Schwartz KM, Luceri RM, Packer DL, Rubin AM, Kowey PR. Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 1996;28:418-422.
13. Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone for supraventricular tachyarrhythmias. Am J Cardiol 1996;78:430-434.